We are on a global mission

to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases.

PlatformPlatform

Platform

Exclusive license to XpressCF™, an industrialized cell-free protein synthesis platform, for the vaccine field allowing: (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.

PeoplePeople

People

Assemblage of preeminent vaccinologists, vaccine developers & biotech company-builders joined together to harness the platform to create positive synergies to optimize development.

VaccineVaccine

Vaccines

Endeavoring to deliver potentially superior and novel vaccines, beginning with its lead program: A broad-spectrum pneumococcal conjugate vaccine.

Well-FinancedWell-Financed

Well-Financed

Backed by a world-class syndicate of private equity, venture capital, institutional & corporate venture investors.

Change the Shape of Vaccine Research. Join Our Team.     View Open Positions